Loading data for BIO — first visit, this takes a few seconds.

Bio-Rad Laboratories, Inc. (BIO)

NYSE: BIO · Real-Time Price · USD

388.51

+7.55 (1.98%)

At close: Sep 10, 2026, 8:00 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	369
Market Cap	9.86B
Revenue (ttm)	2.59B
Net Income (ttm)	222M
	1.07
	8.22
	44.86
	36.77
P/B (ttm)	1.37
P/S (ttm)	3.81
Earnings Date	Oct 29, 2026

Ask	396.23
Volume	285,327
Avg. Volume (20D)	304,844
Open	380.62
Previous Close	380.96
Day's Range	380.23 - 389.83
52-Week Range	236.73 - 396.23
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About BIO

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materia...

[Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Feb 27, 1980

Employees 7,450

Stock Exchange NYSE

Ticker Symbol BIO

Website https://www.bio-rad.com

Full Company Profile

Financial Performance

In 2025, Bio-Rad Laboratories's revenue was 2.58B, an increase of 0.65% compared to the previous year's 2.57B. Earnings were 759.9M, a decrease of -141.2%.

Financial Statements

Earnings Surprise

Bio-Rad Laboratories has released their quarterly earnings on Aug 4, 2026:

Revenue of $651M misses estimates by $0, with -0.09% YoY decline.
EPS of 2.62 exceeds estimates by 0.87, with 0.38% YoY growth.

Next Earnings Release

Bio-Rad Laboratories, Inc. is scheduled to release its earnings on Oct 29, 2026, after market closes.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · Zacks

Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?

BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

3 weeks ago · Zacks

Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

4 weeks ago · Insider Monkey

Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost?

When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues ...